Comparison · NCT00092677-109504b5
EZ/Simva 10/40 mg vs Placebo: Incident Cancer
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. EZ/Simva 10/40 mg vs Placebo: Incident Cancer. Trial comparisons, record NCT00092677-109504b5. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00092677-109504b5
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.111 | 0.0928 | 0.133 | wilson | |
| Risk in group 2 | 0.0753 | 0.0601 | 0.0941 | wilson | |
| Risk difference, group 1 minus group 2 | 0.036 | 0.00962 | 0.0625 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.48 | 1.11 | 1.97 | log | |
| Odds ratio, group 1 over group 2 | 1.54 | 1.12 | 2.11 | log | |
| Number needed to treat, for one more participant with the outcome on EZ/Simva 10/40 mg than on Placebo | 27.8 | 16 | 104 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | EZ/Simva 10/40 mg | Ezetimibe 10 mg + Simvastatin 40 mg | 105 | 943 | OG000 |
| Group 2 | Placebo | 70 | 929 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- POST_HOC
- Title
- Incident Cancer
- Description
- Number of participants with incident cancer
- Time frame
- Entire follow-up (median = 4.35 years)
- Population
- One patient from the 944 patients randomized to ezetimibe/simvastatin 10/40 mg did not receive study medication and was not included.
Source ClinicalTrials.gov
Trial
- Title
- An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)
- NCT number
- NCT00092677
- Phases
- PHASE3
- Conditions
- Aortic Stenosis
- Interventions
- ezetimibe (+) simvastatin, Comparator: Placebo
- Lead sponsor
- Organon and Co
- Results first posted
- 2009-05-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00092677?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00092677-109504b5